Adam Feuerstein

Try Jim Cramer's Action Alerts PLUS
CLICK HERE NOW

Neurocrine Partnering With Pfizer on Insomnia Drug

12/19/02 - 11:49 AM EST

Adam Feuerstein

Neurocrine BiosciencesNBIX has landed drug giant PfizerPFE as a partner for its experimental insomnia medicine Indiplon.

Under terms of the deal, Pfizer will make an initial $100 million payment to the San Diego-based biopharmaceutical firm, and up to $300 million in future milestone payments. Pfizer gets rights to sell Indiplon outside the U.S. in exchange for undisclosed royalty payments to Neurocrine. Both companies will co-develop and co-market the drug in the U.S.

Neurocrine said it hopes to submit Indiplon to the Food and Drug Administration by the end of 2003.

Last month, Neurocrine released positive results from the first late-stage study of Indiplon in a capsule formulation. Four additional phase III studies with an Indiplon capsule are being conducted, along with three phase III trials with a tablet form of the drug. The studies will be used eventually to support an approval application for multiple indications associated with insomnia.

If approved, Indiplon will compete against prescription sleeping pills such as Ambien, which is marketed by Sanofi-SynthelaboSNY.

As part of its partnering agreement, Pfizer said it will support the creation of a 200-member Neurocrine salesforce to sell Indiplon as well as Pfizer's antidepressant drug, Zoloft. After Indiplon launches in the U.S., Pfizer will also give Neurocrine loans totaling $175 million.

Neurocrine shares were up 4% to $44.25 in Thursday trading. Pfizer shares were up 10 cents, to $30.38.





Adam Feuerstein



05/19/08
Cramer on Top Searched Stocks: Yahoo!

Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.


05/17/08
Jim Cramer's Best Blogs

Catch up on his thinking on the hottest topics of the past week.


04/26/08
Coming Week: Make or Break

Investors will have to deal with a Fed meeting and another flood of earnings and economic data.


05/19/08
Top Rocket Stocks: Ensco

Ensco International and Echelon have the potential to move higher in coming days.


04/28/08
Monday's Analysts' Upgrades, Downgrades

See who made what calls.


05/19/08
Telecom Giants See a Savior in Video

The addition of video is helping telecom companies compete against cable and satellite companies.


05/19/08
Contract Expiration Tempers Oil's Rise

The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.


05/19/08
Analysts' Upgrades, Downgrades: Amazon

See who made what calls.


Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Sign up for our FREE newsletters now.

Keep on top of the market and the critical information you need to make more profitable investing decisions.

  • Cramer's Daily Booyah!
  • Before the Bell

Privacy Policy

See All Free Newsletters

Premium Stock Ideas
Access Action Alerts Plus to find out Cramer’s latest picks now!